25 April 2023
BerGenBio ASA – Key information relating to the preferential rights issue
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT
Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) earlier today, on 25 April 2023, regarding the resolution by the Company’s board of directors to propose that the Company carries out a share capital increase, by way of a partly underwritten rights issue, to raise gross proceeds of up to NOK 250 million (the “Rights Issue”).
Date on which the terms and conditions of the preferential rights issue were announced: 25 April 2023
Last day including right: 22 May 2023
Ex-date: 23 May 2023
Record Date: 24 May 2023
Date of approval: 22 May 2023
Maximum number of new shares: 2,500,000,000
Subscription price: Minimum NOK 0.10 and maximum NOK 10
Ratio preferential rights: To be announced when the final number of new shares is determined
Subscription ratio: To be announced when the final number of new shares is determined
Managers: Arctic Securities AS and Carnegie AS
Will the rights be listed: The Company will apply for listing of the preferential rights on the Oslo Stock Exchange
ISIN for the preferential rights: To be announced when clarified
Other information: The subscription price for the new shares to be issued in the Rights Issue, and thus the final number of new shares and the exact amount of the share capital increase will be proposed by the board of directors, based on a recommendation from the managers, the day prior to the annual general meeting to be held on 22 May 2023 (the “AGM”). See the stock exchange announcement published earlier today, on 25 April 2023, for further information regarding the Rights Issue. The rights issue is subject to approval by the AGM. Notice of the AGM will be sent on 28 April 2023.
This information is published in accordance with the requirements of the Continuing Obligations.
For further information, please contact:
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Graham Morrell
graham.morrell@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
